Conor Killmurray | Authors


Wuerstein Discusses the Implications of the KAMILLA Trial and T-DM1 in HER2+ Metastatic Breast Cancer

July 14, 2021

In an interview with Targeted Oncology, Rachel Wuerstein, MD, discussed the implications of the KAMILLA trial and the benefit of T-DM1. Wuerstein also discussed the data that show TDM1’s potential use for patients with HER2-positive metastatic breast cancer beyond the standard-of-care second-line setting.